/
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment human pharmaceutical products.
$1082.20
$22.80 (-2.06%)
Price from 2 days ago
Margins and capital returns are both well above average: 45.56% operating margin, ROIC at 39.78%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 44.7% YoY with margins expanding 7.7pp.
At 38x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Net debt of $36.60B represents 4.1x FCF, leverage limits flexibility.
38.4x earnings, 82.0x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$72.25B
▲ +44.7% YoY
Net Income (TTM)
$25.28B
▲ +94.9% YoY
Op. Margin
47.30%
▲ +7.7pp YoY
ROIC
42.05%
▲ +8.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$11.82B
▲ +138.6% YoY
Op. Cash Flow (TTM)
$20.48B
▲ +90.7% YoY
Net Debt
$38.09B
Cash & Equiv.
$5.28B
5Y CAGR: +21.6%
5Y CAGR: +11.9%
Continue Research